Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz1/2. fázis

Gene Therapy with Modified Autologous Hematopoietic Stem Cells for Patients with Mucopolysaccharidosis Type IIIA

A legfontosabb adatok

Ki végzi
University of Manchester
Hol
Egyesült Királyság1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Fut, nem toboroz
Fázis
1/2. fázis
Résztvevők
5 fő, tervezett
Kezdés
2020. jan. 7.
Befejezés
2026. okt. 30.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene
A regiszteradat frissítve
2025. március 30.

Ki vehet részt

Életkor
3 hónap – 24 hónap
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 21 feltétel megnézéseKevesebb

Ki vehet részt

  • Written informed consent of a legally authorized guardian(s)
  • Age at baseline ≥3 months and ≤24 months
  • Normal cognitive function or mild cognitive deterioration (subject has a Development Quotient (DQ) score ≥80) at baseline as determined by the Bayley Scale of Infant Development-third edition (BSID-III), cognitive domain)
  • Sibling or relative of known MPS IIIA patients with rapidly progressing phenotype, or genotype associated with rapidly progressing phenotype, or presence of somatic features predictive of rapid progression
  • SGSH activity ≤10% of the Lower Limit of Normal as measured in leukocytes, plus either (1) a normal enzyme activity level of at least one other sulfatase (to rule out multiple sulfatase deficiency) as measured in leukocytes or (2) two documented mutations in the SGSH gene
  • Medically stable and able to accommodate the protocol requirements, including travel without placing an undue burden on the patient/patient's family, as determined by the CI

Ki nem vehet részt

  • The subject has received stem cell, gene therapy or enzyme replacement therapy (any route of administration)
  • The subject is currently receiving psychotropic or other medications which, in the CI's opinion, would be likely to substantially confound test results
  • The subject has received any investigational medicinal product (including Genistein) within 30 days prior to the Baseline visit or is scheduled to receive any investigational medicinal product during the course of the study
  • Malignant neoplasia (except local skin cancer) or a documented history of hereditary cancer syndrome. Subjects with a prior successfully treated malignancy and a sufficient follow-up to exclude recurrence (based on oncologist opinion) can be included after discussion and approval by the Medical Monitor
  • The receipt of live vaccinations within 30 days prior to study start
  • The subject has a history of poorly controlled seizures
  • Documented Human Immunodeficiency Virus (HIV) infection (positive HIV RNA and/or anti-p24 antibodies)
  • Myelodysplasia, cytogenetic alterations characteristic of myelodysplastic syndrome and acute myeloid leukaemia, or other serious haematological disorders
  • The subject has a medical condition or extenuating circumstance that, in the opinion of the CI, might compromise the subject's ability to comply with protocol requirements, the subject's well-being or safety, or the interpretability of the subject's clinical data
  • Visual or hearing impairment sufficient to preclude cooperation with neurodevelopmental testing
  • Subject currently enrolled in other interventional clinical trials
  • Contraindications for MRI scans
  • Homozygous or compound heterozygous for the S298P mutation or any other mutation known to be associated to slow-progressing phenotype
  • Severe behavioural disturbances due to reasons other than MPS IIIA and likely to interfere with protocol compliance, as determined by the CI
  • Known sensitivity to busulfan

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Patients with MPS IIIA have a clinical disorder marked by severe and progressive brain disease and neurological symptoms due to the accumulation of undigested glycosaminoglycans in all cells of the body.

A teljes eredeti leírásKevesebb

This study will be the first in human clinical trial to explore the safety, tolerability and clinical efficacy of ex vivo gene therapy (autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene) in MPSIIIA patients. Following treatment with the gene therapy patients will be followed up for a minimum of 3 years.

A vizsgálat csoportja

  • Haematopoietic stem cell gene therapy for MPS IIIAA vizsgált kezelés

    Open label

    Kezelés: Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase I-II, Study of Autologous CD34+ Haematopoietic Stem Cells Transduced Ex Vivo with CD11b Lentiviral Vector Encoding for Human SGSH in Patients with Mucopolysaccharidosis Type IIIA (MPS IIIa, Sanfilippo Syndrome Type A)
A regiszteradat frissítve
2025. március 30.